Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Sep;28(5):453-9.
doi: 10.1097/BOR.0000000000000308.

Cutaneous lupus erythematosus: updates on pathogenesis and associations with systemic lupus

Jasmine N Stannard  1 , J Michelle Kahlenberg
Affiliations
Review

Cutaneous lupus erythematosus: updates on pathogenesis and associations with systemic lupus

Jasmine N Stannard et al. Curr Opin Rheumatol. 2016 Sep.

Abstract

Purpose of review: Cutaneous lupus erythematosus (CLE) is a common manifestation among systemic lupus patients. There are no U.S. Food and Drug Administration approved therapies for CLE, and these lesions are frequently disfiguring and refractory to treatment. The present review will cover the recent inroads made into understanding the mechanisms behind CLE lesions and discuss promising therapeutic developments.

Recent findings: The definition of cutaneous lupus is being refined to facilitate diagnostic and research protocols. Research into the pathogenesis of CLE is accelerating, and discoveries are now identifying genetic and epigenetic changes which may predispose to particular disease manifestations. Furthermore, unique features of disease subtypes are being defined. Murine work supports a connection between cutaneous inflammation and systemic lupus disease activity. Importantly, human trials of type I interferon blockade hold promise for improving our treatment armamentarium for refractory CLE lesions.

Summary: Continued research to understand the mechanisms driving CLE will provide new methods for prevention and treatment of cutaneous lesions. These improvements may also have important effects on systemic disease activity, and thus, efforts to understand this link should be supported.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest:

None

Figures

Figure 1
Figure 1. Summary of CLE pathogenesis
Triggers for skin inflammation, including UV light, stimulate innate cytokine production from keratinocytes and trigger cell death which can activate nucleic acid signaling pathways. Increased autoantigen exposure on the cell surface encourages immune complex deposition, which can lead to antibody dependent cell-mediated cytotoxicity. Cytokine and chemokine production promotes inflammatory infiltrates which damage tissues, perpetuate the inflammatory cycle and lead to chronic TGFβ signaling which promotes damage and scar. The links between skin inflammation and systemic disease require further study. DC=dendritic cell
See this image and copyright information in PMC

References

    1. Mikita N, et al. Recent advances in cytokines in cutaneous and systemic lupus erythematosus. J Dermatol. 2011;38(9):839–849. - PubMed
    1. Andersen LK, Davis MD. Prevalence of Skin and Skin-Related Diseases in the Rochester Epidemiology Project and a Comparison with Other Published Prevalence Studies. Dermatology. 2016 - PMC - PubMed

    1. Jarukitsopa S, et al. Epidemiology of systemic lupus erythematosus and cutaneous lupus erythematosus in a predominantly white population in the United States. Arthritis Care Res (Hoboken) 2015;67(6):817–828. * This is a retrospective cohort study of predominantly white SLE and CLE patients, which demonstrates that CLE is more common than SLE in men and older adults, but the overall incidences of CLE and SLE are similar.

    1. Gilliam JN, Sontheimer RD. Distinctive cutaneous subsets in the spectrum of lupus erythematosus. J Am Acad Dermatol. 1981;4(4):471–475. - PubMed
    1. Hejazi EZ, Werth VP. Cutaneous Lupus Erythematosus: An Update on Pathogenesis, Diagnosis and Treatment. Am J Clin Dermatol. 2016 - PubMed

MeSH terms

Substances